RT Journal Article
T1 SEOM clinical guideline for treatment of kidney cancer (2017).
A1 Gallardo, E
A1 Mendez-Vidal, M J
A1 Perez-Gracia, J L
A1 Sepulveda-Sanchez, J M
A1 Campayo, M
A1 Chirivella-Gonzalez, I
A1 Garcia-Del-Muro, X
A1 Gonzalez-Del-Alba, A
A1 Grande, E
A1 Suarez, C
K1 Kidney cancer
K1 Molecular pathology
K1 Systemic therapy
AB The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be considered the standard for second and further lines of therapy. Response evaluation for present therapies is a challenge.
PB Springer
YR 2017
FD 2017-10-06
LK http://hdl.handle.net/10668/11796
UL http://hdl.handle.net/10668/11796
LA en
NO Gallardo E, Méndez-Vidal MJ, Pérez-Gracia JL, Sepúlveda-Sánchez JM, Campayo M, Chirivella-González I, et al. SEOM clinical guideline for treatment of kidney cancer (2017). Clin Transl Oncol. 2018 Jan;20(1):47-56
DS RISalud
RD Apr 10, 2025